Versartis Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
13,288.00
170,566.00
182,069.00
201,153.00
81,146.00
Other Current Assets
978.00
2,398.00
2,542.00
4,152.00
562.00
Total Current Assets
14,266.00
172,964.00
184,611.00
205,305.00
81,708.00
Net Property, Plant & Equipment
21.00
714.00
389.00
265.00
798.00
Total Investments and Advances
-
-
-
-
2,383.00
Other Assets
396.00
616.00
327.00
-
8,888.00
Total Assets
14,683.00
174,294.00
185,327.00
205,570.00
94,860.00
Accounts Payable
315.00
-
-
-
1,500.00
Income Tax Payable
-
-
-
247.00
-
Other Current Liabilities
3,668.00
6,925.00
8,827.00
54,256.00
4,093.00
Total Current Liabilities
3,983.00
6,925.00
8,827.00
54,503.00
5,593.00
Other Liabilities
495.00
-
-
-
5,428.00
Total Liabilities
4,478.00
6,925.00
8,827.00
54,503.00
12,104.00
Common Equity (Total)
47,292.00
167,369.00
176,500.00
151,067.00
82,756.00
Total Shareholders' Equity
10,205.00
167,369.00
176,500.00
151,067.00
82,756.00
Total Equity
10,205.00
167,369.00
176,500.00
151,067.00
82,756.00
Liabilities & Shareholders' Equity
14,683.00
174,294.00
185,327.00
205,570.00
94,860.00
Preferred Stock (Carrying Value)
57,497.00
-
-
-
-

About Versartis

View Profile
Address
1020 Marsh Roade
Menlo Park California 94025
United States
Employees -
Website http://www.versartis.com
Updated 09/14/2018
Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L.